(Hypertension. 1997;30:825-829.)
© 1997 American Heart Association, Inc.
Articles |
From the Cellular Physiology Department, National Institute of Cardiology "Ignacio Chávez" (T.C., F.M., V.G.), and Mexican Faculty of Medicine, La Salle University (P.N.), México, D.F.
Correspondence to Verónica Guarner, PhD, Departamento de Fisiología Celular, Instituto Nacional de Cardiología "Ignacio Chávez," Juan Badiano 1, Tlalpan, México, D.F. 14080.
| Abstract |
|---|
|
|
|---|
Key Words: muscle, smooth, vascular insulin glucose endothelin
| Introduction |
|---|
|
|
|---|
There is a poor knowledge of the effects of glucose on vascular contractile responses. Although in the short-term, high glucose levels could inhibit calcium-dependent mechanisms that increase glucose transport,14 15 thus diminishing tension development, only the long-term effects of hyperglycemia have been reported.2 Therefore, the aim of the present report was to study the effects of different glucose and insulin concentrations on the contractile characteristics of the vascular smooth muscle of the rat and to test the participation of endothelin as mediator of the insulin effects.
| Methods |
|---|
|
|
|---|
Experimental Protocol
The vessels were superfused with normal Tyrode's solution (NaCl
136.9 mmol/L, KCl 5.4 mmol/L, CaCl2
1 mmol/L, MgCl2 1.05 mmol/L,
NaHCO3 11.9 mmol/L,
NaH2PO4 0.33 mmol/L, and glucose
5.5 mmol/L) for 15 minutes to allow stabilization and then
were made to contract by adding KCl (40 or 80 mmol/L); afterward
they were washed so that the tension returned to the basal level, and
the stimulus was repeated again. The mean force of these two
contractions was used as the control value and was considered as the
100% contractile response. After this, the arteries were placed in one
of the following situations in separate experiments repeating the
stimulation with KCl to test the contractile response. (1) Arteries
were bathed with Tyrode's solution containing half the amount of
glucose (2.75 mmol/L) or double the normal concentration
(11 mmol/L). (2) Arteries were superfused with 150, 300, or 600
nmol/L of insulin (Eli Lilly). These concentrations were chosen
after testing different doses in our experimental conditions. (3)
Arteries were superfused with different glucose concentrations in the
presence of 300 nmol/L of insulin. (4) Arteries in which the
endothelium was removed by insertion of a metal wire
into the lumen and gentle rolling of the vessel segment on a wetted
filter paper were made to contract in the presence and absence of
insulin (300 nmol/L). (5) Arteries were bathed with insulin (300
nmol/L) and with insulin in the presence of polyclonal
anti-endothelin antibodies. (6) Arteries were bathed with insulin (300
nmol/L) in the presence and absence of mouse normal control
serum without anti-endothelin antibodies. (7) Arteries were bathed with
insulin (300 nmol/L) and with insulin in the presence of
ETA-receptor antagonist PD 151,242 (10
µmol/L). (8) Arteries were superfused with insulin (300
nmol/L) and with insulin in the presence of the
ETB-receptor antagonist BQ-788 (10
µmol/L) (antagonists were bought from Research
Biochemicals International). At the end of each experiment, arteries
were bathed again with normal Tyrode's solution and made to contract
with KCl to verify that there were no important effects secondary to
the incubation time or to repeated exposures to KCl and to prove that
glucose and insulin effects were reversible. This last contraction was
reduced after adding the endothelin-receptor antagonists
because they have long-lasting effects. Endothelial
integrity or removal was verified by adding acetylcholine (1
µmol/L) to the contracted vessel, observing a decrease in the
tension generated when the endothelium was intact and
an increase in arteries without endothelium.
Hyperimmune Anti-Endothelin Serum
Human synthetic ET-1 (Sigma Chemical Co) was conjugated using
glutaraldehyde11 with 100 µg hemocyanin
from the crab Megatura crenulata (Boehringer
Mannheim). Conjugated endothelin (15 to 20 µg) was emulsified in an
equal volume of incomplete Freund's adjuvant and injected
intraperitoneally to immunize a Balb/c mouse. The
inoculation was repeated after 3 and 5 weeks. After 7 weeks, blood was
extracted by cardiac puncture from the ether-anesthetized
mouse, and serum was separated by centrifugation at
1200 rpm for 10 minutes. Serum was stored at -80°C until used. A
1:2000 dilution in normal or modified (by the addition of insulin or
KCl) Tyrode's solution was used to perfuse the arteries.
The antibody's specificity was demonstrated by enzyme-linked immunosorbent assay, which was performed as follows: 50 ng of ET-1 coupled to human albumin per well was adsorbed to a microtiter plate at room temperature overnight. Nonspecific binding sites were blocked with 0.01% of porcine gelatine for 2 hours at 37°C. After the plate was rinsed with PBS-0.1% Tween, 20 serial dilutions (1/500 to 1/64 000) of mouse anti-endothelin antiserum were incubated overnight at 4°C. The plate was then washed with PBS-Tween and a peroxidase conjugated polyclonal anti-mouse IgG (F[ab]-specific) was added. After 1 hour of incubation, the plate was rinsed with PBS-Tween, revealed with o-phenylenediamine, and read spectrophotometrically at 492 nm in a Microplate Autoreader EL311 (Bio-Tek Instruments). The titer of the anti-endothelin antiserum determined with this assay was 1/16 000. Negative controls were made using normal mouse serum and wells filled with uncoupled albumin in which no reaction was observed. Although it is possible that antibodies against hemocyanin (the protein to which ET-1 molecule was bound) were induced, this protein is not found in mammals, and therefore, this antibody would not interfere with our assay.
Statistical Analysis
Mean and standard errors of at least six different arteries were
calculated. When values were expressed as percentages, the percentage
in each experiment was calculated, and the mean was then determined.
Statistical significance of the differences was analyzed using
paired Student's t test and nonparametric
Kruskal-Wallis analysis of variance. Differences were
considered statistically significant when P<.05.
| Results |
|---|
|
|
|---|
Determination of KCl Concentrations
Several doses of KCl were tested to produce contraction of the
vessel. KCl 20 mmol/L produced a small increase in the
contraction force of 75±14 mg (n=10), which increased to 128±15 mg
(n=9) with a KCl dose of 40 mmol/L. A maximal increase of
302±64 mg (n=12) was achieved with an 80 mmol/L dose.
Effects of Different Glucose Concentrations on Vascular
Contractility
When arteries were perfused with different glucose concentrations
and stimulated with KCl (80 mmol/L), their response in the
presence of Tyrode's solution with high glucose (11
mmol/L) was significantly reduced when compared with the
response generated in Tyrode's solution with the normal glucose
concentration of 5.5 mmol/L (from 100% to 84.08±4.25%,
n=6). However, no statistically significant changes were observed with
low glucose concentrations (2.75 mmol/L) (Fig 1
). Control contraction at the end of
this experiment was 103.01±4.7%, n=6.
|
Insulin Effects on Vascular Contractility
We found a dose-dependent increase in force generated per
arterial contraction induced by KCl (40 and 80
mmol/L) in arteries bathed with normal Tyrode's solution
(glucose 5.5 mmol/L) in the presence of insulin. The
maximal increase was obtained with an insulin dose of 300
nmol/L, reaching 156.9±7.62%9 and 120.69±4.08%
(n=10) of the control value with 40 and 80 mmol/L KCl,
respectively (Fig 2
). Control contraction
at the end of this experiment was 98.31±1.07%, n=6. Insulin effect
was not present in arteries without endothelium,
and instead, a nonsignificant decrease of the response of 9.5±7.8%
(n=5) was observed. Insulin also tended to modify force development in
arteries bathed with other glucose concentrations. Although there were
no significant changes with 2.75 mmol/L glucose with any of
the KCl doses used, insulin provoked a significant force increase in
arteries bathed with 11 mmol/L glucose only when the
40 mmol/L KCl was used
(Table
).
|
|
Mediation of Insulin Effects by Endothelin
An insulin-induced modification of vasoconstrictor substances such
as endothelin by endothelial cells was tested in our
experiments using a hyperimmune anti-endothelin serum and
antagonists of endothelin receptors ETA and
ETB, PD 151,242 and BQ-788, respectively. The presence of
the antibody decreased the response of arteries bathed in normal
Tyrode's solution without insulin and stimulated by KCl. This effect
was small and nonsignificant with KCl 40 mmol/L, and
although it remained small with 80 mmol/L KCl, it was
statistically significant. Insulin increased the contractile response
to KCl, showing a higher response with 40 mmol/L KCl than
with 80 mmol/L KCl. Although a slight increase in the
contractile response of arteries to 40 mmol/L KCl in the
presence of insulin and anti-endothelin antibody was still observed,
the response to the hormone was reduced by approximately 73% in the
presence of the antibody. The insulin-induced increase in contractile
response to KCl was no longer present with 80 mmol/L
KCl, with which a nonsignificant decrease in force development was
found (Fig 3
). Contraction without
insulin or antibody at the end of the experiment was 95.92±5.22%,
n=6. Control experiments in which normal mouse serum was used to
perfuse the arteries while they contracted in the presence of 40
mmol/L KCl showed no changes in the tension developed by the
arteries in the presence and absence of insulin.
|
The mediation by endothelin of the insulin effects also was
tested using antagonists of the endothelin receptors
ETA and ETB. Both antagonists
significantly reduced insulin-induced increases in the contractile
response of arteries; PD 151,242 caused a 100% decrease in the
response, and BQ-788 reduced the response to even less tension than
that shown in the control situation without insulin. Furthermore, a
decrease of the tension developed by 40 mmol/L of KCl in
the absence of insulin also was observed with the ETB
receptor antagonist BQ-788 (Fig 3
). Control contraction at
the end of the experiments was reduced in 15% and 45% in the
experiments using the ETA and ETB receptor
antagonists, respectively.
| Discussion |
|---|
|
|
|---|
The contractile response of arteries was modified by the different extracellular glucose levels, showing a significant decrease with high glucose concentrations, a condition similar to that found in IDDM. This effect was probably secondary to the inhibition of mechanisms that increase glucose transport15 in vascular smooth-muscle cells through mobilization of calcium ions that mediate contraction. It has been postulated previously that hyperglycemia impairs contractile activity in muscle16 by diminishing phosphoinositide metabolism.17 18 Although the effects of hyperglycemia could be due to an alteration in endothelial cell metabolism, causing an elevated release of vasodilator substances such as nitric oxide, this possibility was not tested in the present work. The absence of an increase in the contractile response in hypoglycemic conditions in our experiments could be the consequence of a lack of the necessary energy needed to induce a contraction when glucose concentrations are low. The results observed in this experiment suggest that, in the short term, hyperglycemia does not contribute to hypertension in IDDM patients but instead decreases tension generation.
Long-term effects of hyperglycemia have been described previously. These include increased vascular rigidity due to toxic effects on the endothelial cells that result in a decreased endothelium-mediated vascular relaxation, muscle cell hyperplasia, vascular remodeling, and fibronectin and collagen IV overexpression.2 These long-term effects of hyperglycemia could contribute, together with nephropathy, to hypertension in IDDM.
We found an increase in force generated by arterial contraction in the presence of insulin, and the effect was greater as insulin concentrations rose. The insulin effect was absent in arteries in which the endothelium was removed, suggesting participation of the endothelial cells in the insulin response. There have been reports showing that high insulin levels such as those found in patients with insulinoma do not cause hypertension.4 5 6 However, elevated plasma endothelin levels have been found in patients with diabetes mellitus7 and during euglycemic hyperinsulinemic clamp in lean NIDDM men.8 Furthermore, in some reports in which no correlation was found between hyperinsulinemia and hypertension, hypertriglyceridemia was reported to enhance the stimulatory effect of insulin on endothelin release.6 Studies using other species have shown a correlation between high insulin levels and hypertension,5 and in bovine and porcine endothelial cells, insulin stimulates the production and secretion of endothelin.10 11 Insulin induces an increase in ET-1 gene expression.9 Hypertension in diabetes could be the consequence of changes in intracellular calcium levels induced by insulin.1 2 3 13 Insulin has been reported to influence different membrane components that increase or decrease intracellular calcium levels in diverse cell types and contribute to the changes found in vascular smooth-muscle cell tension development.1 2 13 17 18 19 The increase in the contractile response induced by insulin also could be the consequence of a modification of endothelial cell secretion, which was tested in our experiments using a polyclonal anti-endothelin antibody and antagonists of the endothelin receptors ETA and ETB. The use of the antibody slightly decreased the response to 40 and 80 mmol/L KCl of arteries bathed in normal Tyrode's solution without insulin, and the ETB-receptor antagonist reduced the response to 40 mmol/L KCl. This last effect, together with the enormous decrease in the response to insulin to less than the control produced by the ETB-receptor antagonist, suggests that depolarization of endothelial cells by KCl causes endothelin secretion, which stimulates the ETB receptor enhancing the contractile response of vascular smooth muscle. The increase in the contractile response in the presence of insulin was reduced significantly when the anti-endothelin antibody or the antagonist of the endothelin receptors ETA and ETB was added. These results suggest that endothelin mediates the effects of insulin and that the hormone stimulates its liberation from intracellular stores in endothelial cells in the artery maintained in the in vitro chamber in our experimental conditions. Although our antibody was produced against the human ET-1 molecule, we cannot discard its interaction with endothelin-2 or -3 or big endothelin due to high molecular homologies. However, the specificity of the antibody against molecules of the endothelin family is suggested by its having the same kind of effects as the endothelin receptor antagonists. The smaller effect of the antibody compared with that of the receptor antagonists could be due to low affinity or avidity of the antibody. The differences found with the two antagonists suggest that the response is mediated predominantly by the ETB receptor. However, the fact that both antagonists blocked the insulin effect might be the consequence of the loss of specificity to one receptor subtype due to the concentration used.
Insulin effect on arteries stimulated with 80 mmol/L KCl was statistically significant only when glucose concentration was 5.5 mmol/L, whereas when stimulated with 40 mmol/L KCl, the effect was significant with both 5.5 and 11 mmol/L glucose. The absence of an insulin effect with high glucose concentrations when the artery is stimulated with 80 mmol/L KCl could be due to compensation of increased force induced by insulin with the effect of high glucose levels that diminish the contractile response. This compensation is not observed with the lower KCl dose. Therefore, hypertension in patients with NIDDM who have increased levels of glucose and insulin could be a consequence of hyperinsulinemia and hyperglycemia when stimulation of the vessel is not maximal. Although the higher prevalence of hypertension in diabetes could be the result of the above-mentioned intracellular effects of insulin and glucose on smooth muscle contractility, other possible causes such as nervous and renal alterations1 3 19 have been reported.
In conclusion, our results suggest that high levels of both glucose (11 mmol/L) and insulin (300 nmol/L) contribute to hypertension in diabetes, particularly in NIDDM patients, and that the effects of insulin are mediated partly by endothelin.
| Selected Abbreviations and Acronyms |
|---|
|
Received December 30, 1996; first decision January 16, 1997; accepted March 14, 1997.
| References |
|---|
|
|
|---|
2.
Epstein M, Sowers JR. Diabetes mellitus and
hypertension. Hypertension.. 1992;19:403-418.
3. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia, a link between hypertension, obesity and glucose intolerance. J Clin Invest.. 1985;75:809-817.
4. Sawicki PT, Heinemann L, Starke A, Berger M. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia.. 1992;35:649-652.[Medline] [Order article via Infotrieve]
5. Hall JE, Brands MW, Hildebrandt DA, Mizelle HL. Obesity-associated hypertension: hyperinsulinemia and renal mechanisms. Hypertension.. 1992;19:I-45-I-55.
6. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes.. 1996;45:316-321.[Abstract]
7. Takahashi K, Ghatei MA, Lam HC, Halloran DJO, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia.. 1990;33:306-310.[Medline] [Order article via Infotrieve]
8. Ferri C, Carlomagno A, Coassin S, Baldoncini R, Cassone Faldetta MR, Laurenti O, Properzi G, Santucci A, De Mattia G. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes Care.. 1995;18:226-233.[Abstract]
9.
Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken
MR, Shiba T, Quertermous T, King GL. Stimulation of endothelin-1
gene expression by insulin in endothelial
cells. J Biol Chem.. 1991;266:23251-23256.
10. Hattori Y, Kasai K, Nakamura T, Emoto T, Shimodo SI. Effect of glucose and insulin on immunoreactive endothelin 1 release from cultured porcine aortic endothelial cells. Metabolism.. 1991;40:165-169.[Medline] [Order article via Infotrieve]
11. Hu E-M, Levin ER, Pedram A. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes.. 1993;42:351-358.[Abstract]
12. Klip A. Is intracellular Ca2+ involved in insulin stimulation of sugar transport? Fact and prejudice. Can J Biochem Cell Biol.. 1984;62:1228-1236.[Medline] [Order article via Infotrieve]
13. Resnick L. Hypertension and abnormal glucose homeostasis. Am J Med. 1989;87(suppl 6A):17S-22S.
14.
Suzuki E, Kono T. Evidence that insulin causes
translocation of glucose transport activity to the plasma membrane from
an intracellular storage site. Proc Natl Acad Sci
U S A.. 1980;77:2542-2545.
15. Clausen T. The role of calcium in the activation of the glucose transport system. Cell Calcium.. 1980;1:311-325.
16. Avrameas S, Ternynek T, Guesdon JL. Coupling of enzymes to antibodies and antigens. Scand J Immunol. 1978;8(suppl 7):7-23.
17. Green DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med.. 1987;316:599-606.[Abstract]
18. Stralfors P. Insulin stimulation of glucose uptake can be mediated by diacylglycerol in adipocytes. Nature. 1988;335:554-556.[Medline] [Order article via Infotrieve]
19. Reaven GM, Hoffman BB. Hypertension as a disease of carbohydrate and lipoprotein metabolism. Am J Med. 1989;87(suppl 6A):2S-6S.
This article has been cited by other articles:
![]() |
P. V. G. Katakam, C. D. Tulbert, J. A. Snipes, B. Erdos, A. W. Miller, and D. W. Busija Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H854 - H860. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Misurski, S.-Q. Wu, J. R. McNeill, T. W. Wilson, and V. Gopalakrishnan Insulin-Induced Biphasic Responses in Rat Mesenteric Vascular Bed : Role of Endothelin Hypertension, May 1, 2001; 37(5): 1298 - 1302. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Nava, V. Guarner, R. Posadas, I. Perez, and G. Banos Insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H399 - H404. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |